Pathos AI raises $237M to scale AI-driven oncology drug development

Securing the capital for oncology

Pathos AI, a New York-based technology company, has successfully closed a $237 million Series E financing round. This investment brings the company to a post-money valuation of approximately $3 billion. The round was led by the pharmaceutical giant Bristol Myers Squibb, with additional support from the company's existing investors.

The capital is intended to fuel the company's growth as it develops its own pipeline of therapeutic drugs. Unlike many tech companies that provide software for others, Pathos AI is a clinical-stage company that creates its own medical assets. The funding will be used to scale its proprietary technology and move its current programs toward major clinical milestones.

A primary goal for this new capital is to advance JSKN016, which is described as a first-in-class TROP2/HER3 bispecific antibody-drug conjugate. The company wants to move this specific drug toward registrational studies. They are also using the funds to progress other assets like pocenbrodib and a novel ER PROTAC partnered with AstraZeneca.

How the Foundry platform works

At the heart of Pathos AI's operations is a proprietary platform known as Foundry. This system utilizes thousands of specialized AI agents to handle the massive amount of information required for drug development. These agents work together to synthesize various types of data, including clinical results, genomic data, and biological specimen information.

The platform is designed to operate in real time, constantly monitoring the ever-changing competitive landscape of the pharmaceutical industry. By aggregating this totality of information, Foundry identifies the best next decision for each individual drug program. This allows the company to make data-driven choices about which paths to pursue and which to abandon.

The technology aims to provide continuous intelligence throughout the drug's lifecycle. Instead of making static decisions at the start of a project, the AI helps the company pinpoint precise biological sub-populations. It can also steer clinical trial pivots and eliminate high-risk development paths early on to save time and resources.

Improving the probability of success

The core philosophy of Pathos AI is to redesign drug development from first principles. The company uses its AI-native monitoring to guide clinical trials and make portfolio decisions. By using continuously updated probability-of-success calculations, they aim to be more systematic in how they approach new therapies.

CEO Iker Huerga stated that the platform aims to systematically improve the probability of success in drug development. He noted that Foundry has fundamentally accelerated the company's ability to identify promising clinical assets. The goal is to ensure that the right therapies are delivered to the right patient populations by using the AI engine to steer the process.

The company's clinical velocity is a direct result of this AI-steered approach. By integrating these tools, Pathos AI can move through the complex stages of drug discovery more rapidly than traditional methods might allow. The new funding ensures they can scale this engine while actively managing their current portfolio of four active clinical assets.

Expanding the oncology pipeline

Pathos AI has used the Foundry platform to aggressively expand its clinical-stage oncology portfolio over the last several months. This expansion was achieved through a series of rapid strategic transactions. These moves have resulted in the company currently managing four active clinical assets in various stages of development.

The company's pipeline covers a wide range of conditions, including metastatic castration-resistant prostate cancer and multiple myeloma. They are also working on treatments for MET-altered non-small-cell lung cancer and ER+/HER2- breast cancer. Each of these programs benefits from the AI's ability to analyze complex biological data to find effective treatments.

One of the most significant assets being prioritized is the TROP2/HER3-expressing solid tumor treatment. By focusing on these specific targets, Pathos AI hopes to create highly specialized medicines. The combination of high-level AI analysis and clinical-stage expertise positions the company as a unique player in the biotech space.